(UroToday.com) Platinum based chemotherapy is the mainstay of first-line treatment for medically eligible patients with advanced urothelial carcinoma. Unfortunately, up to 50% of patients are unable to receive cisplatin, and disease progression often develops even for patients who receive cisplatin. Immunotherapy with checkpoint blockade are a standard of care option for platinum-ineligible patients or those who have progressed on platinum therapy.